About this episode

The episode discusses the challenges in improving drug efficacy for inflammatory bowel disease and the FDA's approach to rare disease treatments with insights from Cameron Turtle of Spyre Therapeutics.

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental IBD medications, and whether the drug industry is scraping the barrel in the search for better treatments. We also discuss the latest news in the life sciences, including the ongoing debate between the FDA and UniQure over its Huntington's disease therapy, as well as Moderna's mammoth patent settlement.

People in this episode

Guest: Cameron Turtle

Topics covered

• inflammatory bowel disease
• drug efficacy
• FDA regulations
• rare disease treatments
• life sciences news

Keywords

• IBD
• drugmakers
• FDA
• rare diseases
• Huntington's disease
• Moderna
• patent settlement

Mentioned in this episode

Organizations: Food and Drug Administration, Spyre Therapeutics, UniQure, Moderna

More episodes of The Readout Loud

• 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts · April 23, 2026 · 38 min
• 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment · April 16, 2026 · 50 min
• 396: A new trick for old science, and biotech VCs' scrambled playbook · April 9, 2026 · 32 min
• 395: Biotech investors' plea to Trump, and a busy M&A week · April 2, 2026 · 32 min
• 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy · March 26, 2026 · 26 min
• 393: A conversation with the 'godfather' of biotech · March 20, 2026 · 45 min

Explore listener stats, chart rankings, contacts and more on the The Readout Loud podcast page.